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Introduction
Chromium is a trace element that is essential to human
health. It is also widely used in various industries.
Chromium exists in both metallic and valence states,
with hexavalent chromium being the most toxic and
carcinogenic. Strongly oxidizing and corrosive, hexa-
valent chromium salts such as potassium dichromate
or chromic acid cause local dermal effects and systemic
toxicity when they enter the body through the skin.
Local dermal effects, including chrome holes, contact
dermatitis and chemical burns, are commonly seen in
occupational exposure cases. On the other hand, sys-
temic toxicity of hexavalent chromium, which is com-
monly seen after intentional exposure, causes intense
gastrointestinal bleeding, renal failure, intravascular
hemolysis, liver damage, shock, coma, and even death.1
Severe acute chromium poisoning following dermal
involvement has rarely been reported.2–5 We report a
case of acute chromium poisoning that resulted from
extensive dermal exposure to hexavalent chromium in
an electroplating tank.
Case Report
A 22-year-old electroplating worker entered a 3-
meter high electroplating tank to clean its interior.
Although he noticed that the electroplating solution
had not completely drained away and his legs were
immersed in the solution, he continued his cleaning
work. The electroplating solution was later identified
as chromic acid. The worker experienced a pricking pain
over his lower limbs within 10 minutes. He left the tank
immediately and washed his legs with a copious amount
of water. However, his condition deteriorated, with sub-
sequent presentations of nausea, vomiting, abdominal
pain, dyspnea and dizziness.
Three hours after exposure, he visited our emer-
gency department for help. On arrival, physical exam-
ination revealed an alert and afebrile patient (blood
pressure, 118/78 mmHg; pulse, 94/min) with clear
breath sounds. The noticeable abnormality was the pres-
ence of first-degree chemical burns over both legs with
brown-tinged pigmentation, estimated to be about
15% of total body surface area (TBSA). Laboratory
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workup was remarkable for leukocytosis, with a white
blood cell count of 22,000/mm3, and mild elevation
of creatinine phosphokinase to 450 U/L (normal,
0–140U/L). Blood creatinine and hepatic aminotrans-
ferase levels were within normal limits. Selected labo-
ratory values are shown in Table 1. Under room air,
arterial blood gas was pH 7.4, PCO2 was 37.4 mmHg,
PO2 was 83.3 mmHg, and HCO3 was 22.6 mmol/L.
Methemoglobin level was reported later with a value
of 0.8%. Chest X-ray showed no active lung lesions.
The chromium concentration of the tank solution
was 1.42 M. Initial chromium level of spot urine was
88,208 μg/L (reference, 0–5.2 μg/L). Because of pro-
gressive chromium intoxication, the patient was hos-
pitalized and received adequate fluid replacement
therapy. Chelating therapy with intravenous dimer-
captopropanesulfonate (DMPS) 125mg every 12 hours
was started on day 1 post exposure. Intravenous N-
acetylcysteine 50 mg/kg every 4 hours and ascorbic
acid 100 mg every 12 hours were also used as adjuvant
therapy.
Oliguria with increasing serum creatinine level
developed within 24 hours. In spite of emergent
hemodialysis, acute pulmonary edema with subsequent
respiratory failure developed on day 3. The patient
was intubated and placed on mechanical ventilation.
Transient liver function impairment (peak alanine
aminotransferase level of 235 U/L on day 3) and ele-
vated creatinine phosphokinase (peak level of 607U/L
on day 4) were also noted. Anemia and thrombocy-
topenia developed on day 5. Continuous venovenous
hemofiltration and plasmapheresis were also insti-
tuted on day 3 and chelating therapy with DMPS and
N-acetylcysteine were continued. Daily chromium
concentrations in dialysate were 763, 250, 79, and
61 μg/L from day 5 through to day 8, respectively.
Although the patient developed multiple skin
chrome ulcers and had prolonged acute renal failure,
his condition gradually improved. On day 10, he was
transferred to the general ward and no longer required
hemofiltration, plasmapheresis, or therapy with DMPS
and N-acetylcysteine. Acute renal failure was managed
with hemodialysis until day 30. He was discharged 
on day 33 without the need of supplemental oxygen
or hemodialysis. Follow-up at the outpatient clinic for
3 months did not reveal the presence of any organ
dysfunction. The Details of serial urine chromium
and serum creatinine measurements are shown in
Figure 1.
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Table 1. Selected laboratory values of a 22-year-old man following transdermal exposure to hexavalent chromium*
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 13
WBC (4,500–11,000/mm3) 22,000 17,500 14,500 15,900 8,400 10,100 12,000 13,700
Segmented neutrophils/lymphocytes (%) 97/1 90/4 84/12 95/1 89/7 97/3 86/7 72/18
Hemoglobin (14–18 g/dL) 16.7 15.9 15.3 16.5 12.5 12.1 14.1 12.3
Platelets (150–400 × 103/mm3) 346 301 220 164 104 96 118 343
Sodium (135–147 mmol/L) 136 138 126 132 138 142 138 131
Potassium (3.4–4.7 mmol/L) 3.0 3.9 4.4 3.4 3.3 2.7 2.6 3.7
Chloride (100–114 mmol/L) 99 92
Calcium (8.4–10.6 mg/dL) 7.7 6.4 7.8
BUN (7–20 mg/dL) 18 29 37 35 28 30 22 47
Creatinine (0.5–1.5 mg/dL) 1.2 2.6 8.1 6.8 4.6 3.6 2.6 9.3
ALT (0–40 U/L) 32 235 204 68 65 134 107
AST (5–45 U/L) 60 780 674 24 65 68 43
Creatinine phosphokinase (0–140 U/L) 450 597 607 222 186
*Continuous venovenous hemofiltration was performed on days 3–10, and hemodialysis was carried out on days 10–30. WBC = white blood cell count; 
BUN = blood urea nitrogen; ALT = alanine aminotransferase; AST = aspartate aminotransferase.
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Figure 1. Sequential change in chromium and creatinine levels.
Discussion
Systemic toxicity from transdermal exposure to hexa-
valent chromium should not be overlooked. Previous
reports showed significant morbidity and mortality
among cases who had chromic burn > 10% TBSA. Two
cases died with external burns of 10% and 40% of TBSA
caused by chromic acid,2,5 and a 20% TBSA burn pro-
duced hepatic damage, acute renal failure and anemia
in another patient.6 Even a small burn of 1% TBSA
might result in significant illness.3
The absorption of hexavalent chromic ions through
the skin is assumed to be rather rapid. In general,
peak blood level can be reached within 5 hours after
skin exposure.7,8 Organ damage can occur thereafter. In
our case, the kidney was the main target organ. While
the skin lesions were relatively self-limited, this patient
manifested acute renal failure complicated with acute
respiratory failure for a prolonged period. Serum cre-
atinine level did not return to normal until 70 days
after exposure. In addition, transient liver function im-
pairment and elevated creatinine phosphokinase were
also noted. Certain severe manifestations, such as intense
gastrointestinal bleeding, intravascular hemolysis, shock
and coma, were not observed in our case.
Chromium is mainly excreted through urine, with
an initial half-life of 2–3 days, followed by a terminal
half-life of about 1 month.9 Initial urine chromium level
in this case was 88,208 μg/L, which decreased rapidly
to 292 μg/L on day 4. Nevertheless, urine chromium
levels remained elevated until 3 months after exposure,
hinting that chromic ion reenters the blood circulation
slowly when it is distributed into extravascular spaces.
Supportive measures are considered as the main-
stay in the management of acute chromium poison-
ing. Although chromium is primarily excreted through
urine, extracorporeal removal measures, such as hemo-
dialysis, hemoperfusion or peritoneal dialysis, are not
helpful in removing chromium from the body.10
Hemodialysis in our case was implemented for acute
renal failure complicated with acute pulmonary edema,
not for chromium removal. Exchange transfusion might
be another choice to reduce blood chromium concen-
tration, but its effect on prognosis remains unclear.11
Based on animal studies, several medications have
been recommended in treating chromium poisoning.
Among them, ascorbic acid has the potential capacity
to enhance the reduction of hexavalent chromium to
the less toxic trivalent chromium, while N-acetylcysteine
and DMPS may significantly increase the total amount
of chromium excretion.12–14 N-acetylcysteine and
DMPS were both administered to our patient 6 hours
after chromium exposure. However, he did not avoid
developing life-threatening phenomena, such as acute
renal failure and pulmonary edema.
Early aggressive excision of exposed skin is an alter-
native way to decrease the systemic toxicity from der-
mal chromium exposure. One patient who had a 10%
TBSA burn caused by chromic acid did not develop
systemic toxicity when excision of the burned area
was performed 7 hours post exposure.4
In summary, we have reported a case of acute
chromium poisoning from dermal exposure. It illus-
trated that absorption of chromium from a 15% burn
of TBSA could result in severe systemic toxicity. There-
fore, the consequences of transdermal exposure to
hexavalent chromium should not be overlooked.
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